A tryptamine-derived catecholaminergic enhancer, (-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP], attenuates reinstatement of methamphetamine-seeking behavior in rats

Neuroscience

Volumn 165, Issue 2, 2010, Pages 300-312

  Hiranita, T ^a   Yamamoto, T ^b   Nawata, Y ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NAGASAKI INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

craving; dopamine; methamphetamine; reinstatement; relapse; self administration

Indexed keywords

1 (BENZOFURAN 2 YL) 2 PROPYLAMINOPENTANE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; METHAMPHETAMINE; SODIUM CHLORIDE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSOCIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; REPEATED DRUG DOSE;

ADRENERGIC AGENTS; AMPHETAMINE-RELATED DISORDERS; ANIMALS; BENZAZEPINES; BENZOFURANS; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, CLASSICAL; CUES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTINCTION, PSYCHOLOGICAL; MALE; METHAMPHETAMINE; RATS; RATS, WISTAR; SELF ADMINISTRATION; SULPIRIDE;

EID: 71549136145     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.10.055     Document Type: Article

References (61)

1. Alleweireldt A.T., Kirschner K.F., Blake C.B., and Neisewander J.L. D1-receptor drugs and cocaine-seeking behavior: investigation of receptor mediation and behavioral disruption in rats. Psychopharmacology 168 (2003) 109-117
2. Alleweireldt A.T., Weber S.M., Kirschner K.F., Bullock B.L., and Neisewander J.L. Blockade or stimulation of D1 dopamine receptors attenuates cue reinstatement of extinguished cocaine-seeking behavior in rats. Psychopharmacology 159 (2002) 284-293
3. Altshuler H., Weaver S., and Phillips P. Intragastric self-administration of psychoactive drugs by the rhesus monkey. Life Sci 17 (1975) 883-890
4. Anggadiredja K., Nakamichi M., Hiranita T., Tanaka H., Shoyama Y., Watanabe S., and Yamamoto T. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 29 (2004) 1470-1478
5. Anggadiredja K., Sakimura K., Hiranita T., and Yamamoto T. Naltrexone attenuates cue-but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward. Brain Res 1021 (2004) 272-276
6. Beuming T., Kniazeff J., Bergmann M.L., Shi L., Gracia L., Raniszewska K., Newman A.H., Javitch J.A., Weinstein H., Gether U., and Loland C.J. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11 (2008) 780-789
7. Cao J., Kulkarni S.S., Husbands S.M., Bowen W.D., Williams W., Kopajtic T., Katz J.L., George C., and Newman A.H. Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4′-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents. J Med Chem 46 (2003) 2589-2598
8. Cervo L., Carnovali F., Stark J.A., and Mennini T. Cocaine-seeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors. Neuropsychopharmacology 28 (2003) 1150-1159
9. Cervo L., Cocco A., Petrella C., and Heidbreder C.A. Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 10 (2007) 167-181
10. Desai R.I., Kopajtic T.A., Koffarnus M., Newman A.H., and Katz J.L. Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25 (2005) 1889-1893
11. Edwards S., Whisler K.N., Fuller D.C., Orsulak P.J., and Self D.W. Addiction-related alterations in D1 and D2 dopamine receptor behavioral responses following chronic cocaine self-administration. Neuropsychopharmacology 32 (2007) 354-366
12. Fischman M.W., Foltin R.W., Nestadt G., and Pearlson G.D. Effects of desipramine maintenance on cocaine self-administration by humans. J Pharmacol Exp Ther 253 (1990) 760-770
13. Gal K., and Gyertyan I. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend 81 (2006) 63-70
14. Gilbert J.G., Newman A.H., Gardner E.L., Ashby Jr. C.R., Heidbreder C.A., Pak A.C., Peng X.Q., and Xi Z.X. Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 57 (2005) 17-28
15. Hamabe W., Fujita R., Yasusa T., Yoneda F., Yoshida A., and Ueda H. (-)1-(Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors. Cell Mol Neurobiol 20 (2000) 695-702
16. Henningfield J. Nicotine medications for smoking cessation. N Engl J Med 333 (1995) 1196-1203
17. Hiranita T., Anggadiredja K., Fujisaki C., Watanabe S., and Yamamoto T. Nicotine attenuates relapse to methamphetamine-seeking behavior (craving) in rats. Ann N Y Acad Sci 1025 (2004) 504-507
18. Hiranita T., Nawata Y., Sakimura K., Anggadiredja K., and Yamamoto T. Suppression of methamphetamine-seeking behavior by nicotinic agonists. Proc Natl Acad Sci U S A 103 (2006) 8523-8527
19. Hiranita T., Nawata Y., Sakimura K., and Yamamoto T. Methamphetamine-seeking behavior is due to inhibition of nicotinic cholinergic transmission by activation of cannabinoid CB1 receptors. Neuropharmacology 55 (2008) 1300-1306
20. Hiranita T., Soto P.L., Newman A.H., and Katz J.L. Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther 329 (2009) 677-686
21. Kato K., Hayako H., Ishihara Y., Marui S., Iwane M., and Miyamoto M. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 260 (1999) 5-8
22. Katz J.L., Izenwasser S., Kline R.H., Allen A.C., and Newman A.H. Novel 3alpha-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. J Pharmacol Exp Ther 288 (1999) 302-315
23. Katz J.L., Kopajtic T.A., Agoston G.E., and Newman A.H. Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J Pharmacol Exp Ther 309 (2004) 650-660
24. Katz J.L., Libby T.A., Kopajtic T., Husbands S.M., and Newman A.H. Behavioral effects of rimcazole analogues alone and in combination with cocaine. Eur J Pharmacol 468 (2003) 109-119
25. Knoll J., Miklya I., Knoll B., Marko R., and Racz D. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. Life Sci 58 (1996) 2101-2114
26. Kreek M. Opiates, opioids and addiction. Mol Psychiatry 1 (1996) 232-254
27. Le Foll B., and Goldberg S.R. Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol Sci 26 (2005) 287-293
28. Loland C.J., Desai R.I., Zou M.F., Cao J., Grundt P., Gerstbrein K., Sitte H.H., Newman A.H., Katz J.L., and Gether U. Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73 (2008) 813-823
29. Magyar K., Lengyel J., Bolehovszky A., Knoll B., Miklya I., and Knoll J. The fate of (-)1-(benzofuran-2-yl)-2-propylaminopentane. HCl, (-)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain. Eur J Drug Metab Pharmacokinet 27 (2002) 157-161
30. Martin T.J., Kim S.A., Buechler N.L., Porreca F., and Eisenach J.C. Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. Anesthesiology 106 (2007) 312-322
31. Miklya I., and Knoll J. Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Life Sci 72 (2003) 2915-2921
32. Natesan S., Reckless G.E., Barlow K.B., Nobrega J.N., and Kapur S. Amisulpride the "atypical" atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophr Res 105 (2008) 224-235
33. Newman A.H., Kline R.H., Allen A.C., Izenwasser S., George C., and Katz J.L. Novel 4′-substituted and 4′,4′′-disubstituted 3 alpha-(diphenylmethoxy)tropane analogs as potent and selective dopamine uptake inhibitors. J Med Chem 38 (1995) 3933-3940
34. Oei T.P., Singer G., and Jefferys D. The interaction of a fixed time food delivery schedule and body weight on self-administration of narcotic analgesics. Psychopharmacology 67 (1980) 171-176
35. Perrault G., Depoortere R., Morel E., Sanger D.J., and Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280 (1997) 73-82
36. Platt D.M., Rowlett J.K., and Spealman R.D. Noradrenergic mechanisms in cocaine-induced reinstatement of drug seeking in squirrel monkeys. J Pharmacol Exp Ther 322 (2007) 894-902
37. Rothman R.B., and Baumann M.H. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479 (2003) 23-40
38. Schenk S., and Gittings D. Effects of SCH 23390 and eticlopride on cocaine-seeking produced by cocaine and WIN 35,428 in rats. Psychopharmacology 168 (2003) 118-123
39. Schneider L.H., Gibbs J., and Smith G.P. D-2 selective receptor antagonists suppress sucrose sham feeding in the rat. Brain Res Bull 17 (1986) 605-611
40. Schoemaker H., Claustre Y., Fage D., Rouquier L., Chergui K., Curet O., Oblin A., Gonon F., Carter C., Benavides J., and Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280 (1997) 83-97
41. Self D.W., Barnhart W.J., Lehman D.A., and Nestler E.J. Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271 (1996) 1586-1589
42. Self D.W., Karanian D.A., and Spencer J.J. Effects of the novel D1 dopamine receptor agonist ABT-431 on cocaine self-administration and reinstatement. Ann N Y Acad Sci 909 (2000) 133-144
43. Shalev U., Grimm J.W., and Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 54 (2002) 1-42
44. Shimazu S., Takahata K., Katsuki H., Tsunekawa H., Tanigawa A., Yoneda F., Knoll J., and Akaike A. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. Eur J Pharmacol 421 (2001) 181-189
45. Shimazu S., Tamashiro A., Yoneda F., and Knoll J. The L-DOPA-sparing effect of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in reserpine-pretreated rats. Life Sci 72 (2003) 1413-1419
46. Shimazu S., Tsunekawa H., Yoneda F., Katsuki H., Akaike A., and Janowsky A. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane. Eur J Pharmacol 482 (2003) 9-16
47. Stefanski R., Justinova Z., Hayashi T., Takebayashi M., Goldberg S.R., and Su T.P. Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls. Psychopharmacology 175 (2004) 68-75
48. Stefanski R., Ladenheim B., Lee S.H., Cadet J.L., and Goldberg S.R. Neuroadaptations in the dopaminergic system after active self-administration but not after passive administration of methamphetamine. Eur J Pharmacol 371 (1999) 123-135
49. Szerman N., Peris L., Mesias B., Colis P., Rosa J., and Prieto A. Reboxetine for the treatment of patients with cocaine dependence disorder. Hum Psychopharmacol 20 (2005) 189-192
50. Tong J., Ross B.M., Schmunk G.A., Peretti F.J., Kalasinsky K.S., Furukawa Y., Ang L.C., Aiken S.S., Wickham D.J., and Kish S.J. Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. Am J Psychiatry 160 (2003) 896-903
51. Tsunekawa H., Noda Y., Miyazaki M., Yoneda F., Nabeshima T., and Wang D. Effects of (R)-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride [(-)-BPAP] in animal models of mood disorders. Behav Brain Res 189 (2008) 107-116
52. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., Gatley S.J., Miller E., Hitzemann R., Ding Y.S., and Logan J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21 (2001) 9414-9418
53. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Logan J., Wong C., and Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158 (2001) 377-382
54. Vorel S.R., Ashby Jr. C.R., Paul M., Liu X., Hayes R., Hagan J.J., Middlemiss D.N., Stemp G., and Gardner E.L. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 22 (2002) 9595-9603
55. Weiss F., Markou A., Lorang M.T., and Koob G.F. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res 593 (1992) 314-318
56. Werner T.E., Smith S.G., and Davis W.M. A dose-response comparison between methadone and morphine self-administration. Psychopharmacologia 47 (1976) 209-211
57. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., and Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2 (1996) 699-703
58. Wu J.C., Bell K., Najafi A., Widmark C., Keator D., Tang C., Klein E., Bunney B.G., Fallon J., and Bunney W.E. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology 17 (1997) 402-409
59. Xi Z.X., and Gardner E.L. Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS drug reviews 13 (2007) 240-259
60. Xi Z.X., Newman A.H., Gilbert J.G., Pak A.C., Peng X.Q., Ashby Jr. C.R., Gitajn L., and Gardner E.L. The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31 (2006) 1393-1405
61. Yoneda F., Moto T., Sakae M., Ohde H., Knoll B., Miklya I., and Knoll J. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Bioorg Med Chem 9 (2001) 1197-1212